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Abstract
Background: We aimed to evaluate the differences in the rates and predictive factors for ipsilateral breast tumor
recurrence (IBTR) after breast-conserving surgery (BCS) between ductal carcinoma in situ (DCIS) and invasive breast
cancer. And, we evaluated the impact of IBTR on overall survival and distant metastasis.
Methods: We retrospectively reviewed 322 consecutive patients with DCIS or invasive breast cancer who
underwent BCS between 2004 and 2010. We evaluated the rates of IBTR of DCIS and invasive breast cancer.
Univariate and multivariate analyses were performed to determine the predictive factors for IBTR, and survival
rates were analyzed with Kaplan-Meier estimates.
Results: With a median follow-up period of 57 months, 5 (10 %) out of 50 DCIS patients and 14 (5.1 %) out of
272 invasive cancer patients had developed IBTR. Factors associated with IBTR on univariate and multivariate
analyses were positive resection margin status in DCIS and omission of radiotherapy in invasive cancer,
respectively. The hormone receptor negativity was strong independent predictive factors for IBTR in both DCIS
and invasive breast cancer. Although the differences of survival curve did not reach statistical significance, the
5-year overall survival and distant metastasis-free survival of invasive cancer patients who suffered IBTR were
inferior to those without (84 vs. 98 % and 63.3 vs. 96.5 %, respectively). Advanced initial stage, lymph node
metastasis and experience of IBTR were associated with poor overall survival and distant metastasis on
univariate and multivariate analyses.
Conclusions: The hormone receptor negativity was revealed as independent predictive factor for IBTR after
BCS in both DCIS and invasive cancer. Experience of IBTR was independent prognostic factor for poor overall
outcome in patients with invasive breast cancer. Aggressive local control and adjuvant therapy should be
made in hormone receptor-negative patients who receive treatment with BCS.
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Background
Breast cancer is the second most common newly diag-
nosed malignancy in Korean women. The number of
early breast cancer detections has increased due to the
development of screening programs, and the rates of
breast-conserving surgery (BCS) have also increased.
The rate of BCS was as high as 62 % at 2012, according
to the nationwide database of the Korean Breast Cancer
Society.
Breast-conserving treatment, defined as lumpectomy
or quadrantectomy followed by radiation therapy, is the
standard surgical method in the treatment of invasive
breast cancer. The results of 20 years of follow-up from
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-06 trial showed no significant differences in
disease-free survival, distant disease-free survival, or
overall survival between the BCS and mastectomy
groups [1]. However, the incidence of ipsilateral breast
tumor recurrence (IBTR) after BCS is 5–10 % during
5 years of follow-up, and the risk continues over a longer
period of follow-up [1, 2]. Positive margin status, human
epidermal growth factor receptor 2 (HER-2) positivity,
young age, in situ lesions around the tumor, triple-
negative subtype, and lymphovascular invasion (LVI) of
tumors are known as predictive factors for the develop-
ment of IBTR after BCS [3–7]. Nevertheless, the ration-
ale for performing BCS is that the overall survival (OS)
was not different compared to the mastectomy group.
BCS has also been the standard surgical method in pa-
tients with ductal carcinoma in situ (DCIS). The 5-year
rate of IBTR after BCS in DCIS has been reported to be
about 5–10 %. Young age, positive or close resection
margins, and omission of endocrine therapy and radio-
therapy have been associated with an increased risk of
IBTR after BCS in DCIS patients [8–10]. Negative surgi-
cal margins should be obtained for patients with DCIS
after BCS regardless of radiotherapy. Numerous studies
have found that margin thresholds greater than 10 mm
are warranted for the treatment of patients with DCIS
who undergo BCS [9, 11]. There is a difference in the
appropriate margin threshold between DCIS and inva-
sive cancer, and 2014 American Society of Clinical On-
cology (ASCO) guidelines recommend the use of “no
ink on tumor” as the standard for an adequate margin in
invasive cancer [12].
There have been many controversies regarding the ef-
fect of IBTR on distant recurrence and survival. Many
investigators have reported that IBTR after BCS is asso-
ciated with subsequent mortality. Studies showed that
early IBTR within 2 years after BCS was associated with
a higher risk of distant relapse and mortality [13–15].
Clinicopathologic features of the recurrent tumor in-
cluding LVI, high-grade histology, high Ki-67 index,
close/positive margins, and estrogen receptor (ER)
negativity are predictive factors for poor OS after IBTR
[16–18]. Fisher et al. also found a significant association
between IBTR after BCS and OS based on the results of
15 years of follow-up of the NSABP B-06 trial, but they
pointed that IBTR represents a marker rather than a
cause of distant disease [19].
In the current study, we reviewed the medical records
of 322 consecutive patients with stage 0–IIIA breast can-
cer who underwent BCS in a single center with a median
follow-up period of 57 months. The first aim of this
study was to identify the rates of IBTR after BCS in
DCIS and invasive breast cancer and to evaluate the dif-
ferences in the predictive factors for IBTR between DCIS
and invasive breast cancer after BCS. The second aim of
this study was to evaluate the association of IBTR and
OS and distant metastasis in this study population.
Methods
Study patients
We retrospectively reviewed the records of 322 consecu-
tive patients with stage 0 to IIIA breast cancer who
underwent BCS at the Department of Surgery, Chung-
buk National University Hospital, Cheongju, South
Korea, from January 2004 to December 2010. Bilateral
tumors were observed in two patients, and 324 invasive
and in situ breast cancers were treated with BCS. We
excluded patients who received primary chemotherapy.
Because we treated patients with lobular carcinoma in
situ (LCIS) as closed surveillance after pathologic con-
firm by excision or core needle biopsy only, the patients
with LCIS were also excluded. We reviewed the medical
records of each patient for clinical data including age at
diagnosis, follow-up status, and information regarding
outcome. Pathological parameters were evaluated, in-
cluding tumor size, lymph node (LN) metastasis, estro-
gen receptor (ER) status, progesterone receptor (PR)
status, nuclear grade, HER 2 and Ki-67 status, and re-
sults of BCS including resection margins and presence
of intraductal component. The breast cancer stage was
classified according to the American Joint Committee
on Cancer (AJCC) TNM criteria (7th edition).
The surgical procedure consisted of a quadrantectomy
or lumpectomy in all patients and axillary nodal staging
with sentinel LN procedure or axillary dissection for in-
vasive cancers. Axillary LN dissection included level 1
and 2 axillary LNs. For all cases, intraoperative frozen
section diagnoses of surgical margins in eight directions
were performed. When the margins were tumor-positive
on frozen biopsy, additional resections were performed
until the margins were shown to be negative. Surgically
resected specimens were cut into tissue blocks and proc-
essed to provide permanent formalin-fixed paraffin-
embedded sections. Patients with surgical margins were
found to be positive on the permanent sections, most
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patients underwent additional re-excision surgery and
the surgical margins turned out to be negative. Resection
margins were classified to positive (cancer cells on inked
margin), close (≤1 mm from the margin), and negative
(>1 mm from the margin).
ER and PR status were determined by immunohisto-
chemistry, and tumors with 1 % or more positively
stained tumor cells were classified as positive. Any ER-
or PR-positive tumors were considered as hormone re-
ceptor (HR) positive. HR negativity was defined as both
ER-negative and PR-negative. HER2 status was con-
sidered positive if immunohistochemistry was 3+ or
fluorescence in situ hybridization (HER-2/neu to chro-
mosome 17 ratio) was >2.0. Proliferation activity was
assessed by immunostaining with the Ki-67 antibody
(Dako, Carpinteria, CA, USA). Ki67 expression was
scored as the percentage of positive invasive tumor cells
with any nuclear staining and recorded as mean percent-
age of positive cells. The Ki-67 index was evaluated by
one pathologist and the proportion of proliferating cells
was determined by counting at least 500 tumor cells.
Ki67 index ≥14 % was considered as positive.
Hormonal therapy was performed in 236 patients
(73.3 %). Tamoxifen was the most commonly used agent
(136 patients, 57.8 %), followed by aromatase inhibitors
(100 patients, 42.2 %). Adjuvant chemotherapy was per-
formed according to the National Comprehensive Can-
cer Network (NCCN) consensus available at the time of
treatment. The majority of patients (96.3 %) received ad-
juvant radiotherapy. Radiation therapy was administered
with a total dose of 5040 cGy to the whole breast (28 ×
180 cGy). A boost dose with a total of 900 cGy (5 ×
180 cGy) was applied to the tumor bed. Radiation ther-
apy to the whole breast and boost doses were adminis-
tered using photons.
An IBTR was defined as a recurrent in situ or invasive
carcinoma that occurred after BCS in either the skin or
parenchyma of the ipsilateral breast without clinical-
radiologic evidence of regional or distant disease. Distant
failure was defined as all cancers that occurred at sites
other than ipsilateral or contralateral breast or regional
sites. The OS end-point included all deaths.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware statistical package (Version 12 for Windows, SPSS
Inc., Chicago, IL, USA). Rates of IBTR, distant failure,
and OS were calculated using the Kaplan-Meier method.
The significance of differences of the curves for numer-
ous risk factors was determined using the log-rank test.
Logistic regression was used to evaluate the association
between covariates of interest and the probability of
IBTR. Multivariate analyses were performed using Cox
proportional hazards model. Cox proportional hazards
model was used for univariate and multivariate analyses
to determine the hazard ratios and significance of poten-
tial risk factors for OS and distant metastasis-free sur-
vival. Statistical significance was defined as a p value
<0.05.
Results
The median age of the study population at the time of
diagnosis was 51 years (range, 23 to 79). Details on the
distribution of the clinicopathological factors in the
study cohort are displayed in Table 1. Fifty patients
(15.5 %) had stage 0 disease, 233 patients (72.4 %) had
stage I to IIA disease, and 39 patients (12.1 %) had stage
IIB to IIIA disease. Multiple lesions were identified in 29
patients (9.0 %). At first operation, 13 patients were re-
vealed as having positive margin. Of those, seven pa-
tients refused reoperation and six patients underwent
re-excision; the patients who underwent re-excision
were classified as having negative resection margins. Pa-
tients with having close resection margin after first oper-
ation did not undergo reoperation. Subsequently, seven
patients (2.2 %, four patients with DCIS and three with
invasive cancer) were classified as having positive resec-
tion margins, and five patients (1.6 %) were identified as
having close resection margins of less than 1 mm. Radi-
ation therapy was performed in 310 patients (96.3 %),
and hormonal therapy was performed in 236 patients
(73.3 %). Chemotherapy was administered to 198 pa-
tients (61.5 %).
The median follow-up period was 57 months (range
12–133 months). Overall, 19 (5.9 %) out of 322 patients
had developed IBTR. Five (10 %) out of 50 patients with
DCIS and 14 (5.1 %) out of 272 patients with invasive
cancer had developed IBTR. The 5-year IBTR-free sur-
vival of patients with DCIS and invasive cancer was 90.1
and 94.8 %, respectively. Contralateral recurrences were
identified in six out of 272 invasive cancer patients and
regional recurrence involving ipsilateral axilla and supra-
clavicular LN were identified in 4 out of 272 invasive
cancer patients.
Tables 2 and 3 showed the predictive factors for IBTR
in DCIS and invasive cancer, respectively. By univariate
analysis, positive resection margin status and ER and PR
negativity were associated with IBTR in DCIS patients.
In contrast, ER and PR negativity, omission of radiother-
apy, and high Ki67 score were associated with IBTR in
invasive cancer patients. Age less than 40 years showed
marginally significant predictive findings for IBTR in in-
vasive cancer patients. By multivariate analysis, positive
resection margin status (p = 0.007) and ER negativity
(p = 0.03) in DCIS and omission of radiotherapy (p <
0.001) and ER and PR negativity (p = 0.001, p = 0.002) and
high Ki-67 score (p = 0.04) in invasive cancer remained as
significant factors predicting IBTR. Positive resection
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margin status showed no significant association with
IBTR in invasive cancer patients.
At the time of analysis, all patients with DCIS were
alive without distant metastasis. Out of 272 invasive can-
cer patients, 17 patients (6.3 %) were suffering from dis-
tant metastasis and 8 patients (2.9 %) had died. The 5-
year OS and distant metastasis-free survival of 272 inva-
sive cancer patients were 98.7 and 95.6 %, respectively.
Table 4 showed the course of disease of the patients
with IBTR. The treatment of IBTR was mastectomy in
all patients. Although three out of five IBTRs in DCIS
patients were invasive recurrences, all patients with
DCIS were alive without distant metastasis. Rather, all
13 invasive cancer patients who suffered IBTR experi-
enced invasive IBTR. Among 272 invasive breast cancer,
five (38.5 %) out of 13 patients who suffered IBTR
developed distant metastasis and 3 (23.1 %) had died.
The 5-year OS of patients with IBTR was inferior to
those without (84 vs. 98 %). And, the 5-year distant
metastasis-free survival of patients with IBTR was in-
ferior to those without (63.3 vs. 96.5 %). However, the dif-
ferences in outcome did not reach statistical significance.
The univariate and multivariate analyses of potential
prognostic factors for OS and distant metastasis-free
survival in invasive cancer patients are shown in Tables 5
and 6. LN positivity, advanced stage, and experience of




Median, range 51 (23~79)
T stage
Tis 50 (15.5 %)
T1 (≤2 cm) 189 (58.7 %)
T2 (>2 and ≤5 cm) 83 (25.8 %)
N stage
N0 239 (78.1 %)
N1 55 (18.0 %)
N2 12 (3.9 %)
AJCC stage
0 50 (15.5 %)
I–IIA 233 (72.4 %)
IIB–IIIA 39 (12.1 %)
Histology
Ductal in situ 50 (15.5 %)
Invasive ductal 244 (75.8 %)
Invasive lobular 7 (2.2 %)
Others 21 (6.5 %)
Hormonal receptor
Positive 238 (82.1 %)
Negative 49 (16.9 %)
HER2
Negative 235 (73.0 %)
Positive 40 (12.4 %)
Ki-67
Negative 139 (43.2 %)
Positive 173 (53.7 %)
Nuclear grade
Low 38 (11.8 %)
Intermediate 170 (52.8 %)
High 114 (35.4 %)
Resection margin status
Negative 310 (96.3 %)
Close 5 (1.6 %)
Positive 7 (2.2 %)
Hormonal therapy
Done 236 (73.3 %)
Not done 86 (26.7 %)
Chemotherapy
Done 198 (61.5 %)
Not done 124 (38.5 %)
Table 1 Patient, tumor, and treatment characteristics of 322
patients (Continued)
Radiotherapy
Done 310 (96.3 %)
Not done 12 (3.7 %)
Table 2 Univariate and multivariate analyses of predictive risk
factors for IBTR in DCIS (n = 50)
Variables Univariate Multivariate
OR (95 % CI) p value HR (95 % CI) p value
Age <40 years 2.0 (0.2–21.6) 0.56 1.9 (0.2–17.8) 0.54
Tumor size >2 cm 1.1 (0.6–4.2) 0.23 1.2 (0.1–5.3) 0.29
Positive margin
status
4.7 (0.5–14.2) 0.02* 15.6 (2.7–66.3) 0.007*
Multiplicity 2.5 (0.4–4.4) 0.44 2.5 (0.2–2.5) 0.42
High nuclear grade 2 (0.1–9.1) 0.63 1.2 (0.1–11.5) 0.67
EIC positive 1 0.99 1 0.99
Negative ER 9.0 (1.2–65.6) 0.03* 6.7 (1.2–40.5) 0.03*
Negative PR 10.5 (1.1–105.0) 0.04* 8.9 (0.9–79.4) 0.05
Positive HER2 1 0.99 1 0.34
Comedo necrosis 2.5 (0.1–16.3) 0.40 2.2 (0.4–13.6) 0.36
Omission of
radiotherapy
3.6 (0.5–25.8) 0.19 3.4 (0.6–20.1) 0.18
*p < 0.05
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IBTR were associated with poor OS and distant meta-
stasis on univariate analysis. LN positivity (p = 0.03) and
experience of IBTR (p < 0.001) remained as highly sig-
nificant in multivariate analysis for predicting OS and
distant metastasis-free survival.
Discussion
The purpose of this study was to evaluate the differences
in the rates and predictive risk factors for IBTR between
DCIS and invasive breast cancer, from 322 consecutive
patients with primary breast cancer undergoing BCS at a
single center. We also analyzed their prognostic influ-
ence of IBTR on patients’ overall survival and distant
metastasis.
In the current study, 19 (5.9 %) patients, 5 (10 %) out
of 50 with DCIS and 14 (5.1 %) out of 272 with invasive
cancer, had developed IBTR. These results are compar-
able to those of previous studies regarding IBTR after
BCS [1, 2, 7]. In those studies, the incidence of IBTR
after BCS for invasive cancer was found to vary between
5 and 10 % over 5 years, and the risk continues over a
longer period of follow-up. However, our results showed
some high rates of IBTR in comparison to a previous
study using a Korean database, which reported an the
overall 5-year rate of IBTR as low as 1.6 % in invasive
cancer [4]. In that study, patients who did not re-
ceive adjuvant radiotherapy and those with positive
surgical margins were excluded. Because we analyzed
consecutive breast cancer patients who underwent
BCS in a single center, five patients with positive/
close margins and three patients who did not
undergo radiotherapy were included. We therefore
assume these factors to be the reason for our higher
Table 3 Univariate and multivariate analyses of predictive risk
factors for IBTR in invasive cancer (n = 272)
Variables Univariate Multivariate
OR (95 % CI) p value HR (95 % CI) p value
Age <40 years 1.3 (0.8–6.7) 0.06 2.9 (0.9–9.2) 0.07
Tumor size >2 cm 1.1 (0.5–2.1) 0.85 0.9 (0.5–1.9) 0.94
Positive margin
status
1 0.99 1 0.99
Multiplicity 0.78 (0.1–6.3) 0.82 1.2 (0.2–9.8) 0.81
High nuclear grade 1 0.99 2.5 (0.8–7.6) 0.86
EIC positive 1.5 (0.3–6.9) 0.59 1.4 (0.3–6.7) 0.08
Negative ER 7.9 (2.4–26.1) 0.001* 7.5 (2.3–23.8) 0.001*
Negative PR 8.2 (2.2–30.0) 0.002* 7.7 (2.2–27.8) 0.002*
Positive HER2 2.0 (0.3–16.1) 0.50 1.1 (0.7–17.3) 0.95
Positive LVI 1.4 (0.2–10.8) 0.77 1.3 (0.3–11.2) 0.72
Positive Ki-67 4.8 (1.1–21.7) 0.04* 5.0 (1.0–20.8) 0.04*
Omission of
Radiotherapy
5.6 (0.3–17.2) 0.03* 50.0 (12.8–194.5) <0.001*
*p < 0.05
Table 4 Analyses of 19 patients who had experienced IBTR
No. Age Histology of
primary tumor












1 60 DCIS ER + Neg. Not done 12 DCIS none N/A 41 80
2 26 DCIS ER - Pos. Done 13 DCIS none N/A 126 128
3 52 DCIS ER + Pos. Done 14 IDC none N/A 26 30
4 56 DCIS ER - Neg. Not done 20 IDC none N/A 42 114
5 43 DCIS ER - Neg. Done 47 IDC none N/A 52 52
6 31 Metaplastic TN Neg. Done 14 Metaplastic, TN none N/A 30 30
7 45 IDC TN Neg. Done 8 IDC, TN lung 6 18 18 (dead)
8 48 IDC TN Neg. Not done 14 IDC, TN N/A 49 74
9 44 IDC TN Neg. Done 15 IDC, TN N/A 34 34
10 49 IDC TN Neg. Done 16 IDC, TN lung 9 35 35 (dead)
11 33 IDC HER2 Neg. Done 17 IDC, TN N/A 62 69
12 36 IDC Luminal Neg. Done 21 IDC, Luminal bone 10 36 36
13 41 IDC TN Neg. Done 22 IDC, HER-2 lung 15 38 42
14 65 IDC Luminal Neg. Not done 30 IDC, Luminal N/A 36 36
15 43 IDC Luminal Pos. Not done 30 IDC, Luminal N/A 38 47
16 44 IDC TN Neg. Done 34 IDC, TN N/A 52 52
17 51 IDC Luminal Neg. Done 39 IDC, Luminal N/A 49 60
18 48 IDC TN Neg. Done 47 IDC, TN N/A 63 77
19 39 IDC HER2 Neg. Done 52 IDC, HER2 lung 5 78 78 (dead)
Neg. negative, Pos. positive, TN triple negative
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IBTR rate. The 5-year rate of IBTR after BCS in
DCIS has been reported to be about 5–10 % [8, 9, 20].
Our study showed comparable findings, with a rate of
IBTR after DCIS of 10 % with a median follow-up period
of 57 months.
In this study, we wanted to know whether or not there
was a difference, in predictive factors for IBTR between
DCIS and invasive cancer. In patients with DCIS, multi-
variate analysis revealed that positive margin status
and ER negativity remained as independent predictors
for IBTR. In contrast, omission of radiotherapy, HR
negativity, and high Ki67 score were the independent
predictive factors for IBTR in invasive cancer. Al-
though we had a small study population, multiplicity,
young age, and extensive intraductal component
(EIC), LVI, and HER-2 positivity showed little or no
clinical significance as predictive factors for IBTR in
this study. Larger studies with longer follow-up are
needed to understand more detailed predictive factors
for IBTR.
However, in this study, HR negativity was the strong
independent predictive factor for IBTR in both DCIS
and invasive cancer. This is a consistent finding with
others who showed patients with triple-negative breast
cancers behave less favorably than luminal breast can-
cers and almost as poorly as HER2/neu over-expressing
cancers in terms of locoregional recurrence following
BCS [3]. Demicheli et al. analyzed recurrence peak after
BCS according to ER status and showed IBTR risk peak
delay observed in ER-positive tumors than ER-negative
tumors after BCS. They suggest that the microenviron-
ment within the residual breast tissue may enforce
more stringent constraints upon ER-positive breast
tumor cell growth than other tissues, prolonging the
latency of IBTR. This local environment is, however,
apparently less constraining to ER-negative cells [21].
Additionally, there were many studies about the effect
of subtype of IBTR on prognosis. Ishitobi et al. [18]
showed that IBTR with luminal A subtype showed the
most favorable outcome in terms of distant recurrence
than others and breast cancer subtype was an inde-
pendent predictor associated with distant recurrence
after IBTR. In other study, locoregional failure showed
significantly larger effect on mortality and distant dis-
ease in ER-negative patients than in ER-positive pa-
tients [17]. Aggressive local control and adjuvant
therapy should be considered for patients with HR-
negative breast cancer who undergo BCS.
In our study population, all three invasive breast
cancer patients who did not undergo radiotherapy
developed IBTR. Despite our small study population
and the small number of events, these results are
consistent with the findings of NSABP B-06, which
showed that patients treated with radiation remained
with low IBTR as compared to those receiving no radi-
ation through 9 years of follow-up, regardless of age, nodal
status, and tumor size [22]. Radiotherapy should be per-
formed in all patients of invasive cancer who treated
with BCS.
Table 5 Univariate and multivariate analyses of potential risk
factors for overall survival in patients with invasive cancer
(n = 272)
Variables Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Age <40 years 0.6 (0.2–2.4) 0.51 1.2 (1.5–9.7) 0.88
T stage, T2 (vs. T1) 1.8 (0.9–3.2) 0.12 2.1 (0.3–5.7) 0.54
Positive LN 3.6 (1.5–11.3) 0.02* 6.9 (1.2–38.4) 0.03*
Stage, IIB-IIIA 4.8 (1.2–19.6) 0.03* 4.9 (1.6–29.3) 0.02*
IBTR 21.9 (4.7–101.9) <0.001* 31.8 (6.1–165.3) <0.001*
Positive margin
status
1 0.85 1 0.93
Omission of
Radiotherapy
1 0.78 1 0.92
Negative ER 1.6 (0.5–4.4) 0.40 3.1 (0.7–12.3) 0.12
Negative PR 1.8 (0.7–4.9) 0.26 3.4 (0.8–14.3) 0.09
Positive HER2 1.2 (0.1–8.3) 0.92 1 0.95
Positive LVI 1.2 (0.2–1.3) 0.84 2.3 (0.3–18.8) 0.43
Positive Ki-67 1.1 (0.4–2.9) 0.87 1.5 (0.3–5.9) 0.64
High histologic
grade
1 0.84 1 0.97
*p < 0.05
Table 6 Univariate and multivariate analyses of potential risk
factors for distant metastasis in patients with invasive cancer
(n = 272)
Variables Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Age <40 years 1.5 (0.4–5.7) 0.51 1.2 (0.3–4.2) 0.78
T stage, T2 (vs. T1) 1 0.83 1 0.98
Positive LN 4.8 (1.3–17.7) 0.02* 3.4 (0.9–12.3) 0.04*
Stage, IIB–IIIA 3.1 (1.1–8.4) 0.03* 3.83 (1.4–10.8) 0.07
IBTR 11.5 (3.9–33.4) <0.001* 14.4 (4.8–43.1) <0.001*
Positive margin
status
1 0.99 1 0.95
Omission of
Radiotherapy
1 0.99 1 0.90
Negative ER 1.6 (0.5–4.4) 0.39 2.7 (0.1–10.6) 0.25
Negative PR 1.8 (0.6–4.9) 0.22 1.8 (0.7–4.8) 0.90
Positive HER2 1.2 (0.2–8.4) 0.92 1 0.98
Positive LVI 1.2 (1.0–10.1) 0.84 1 0.99
Positive Ki-67 1.1 (0.4–2.9) 0.87 1.2 (0.4–3.0) 0.65
High histologic
grade
1 0.833 1 0.98
*p < 0.05
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Likewise, postoperative radiotherapy after BCS has
known as the standard treatment in DCIS patients. How-
ever, there remains variation in the use of radiotherapy in
favorable type of DCIS. In a series published by Silver-
stein et al., patients with small lesions, with favorable his-
tologies, and of low to intermediate grade with widely
negative margins (>1 cm) treated by BCS alone reported
an IBTR rate as low as 6 % at 5 years [23]. Rudloff et al.
[24] reported that radiotherapy reduced IBTR only in
cases of close margins below 1 cm and the effect of radio-
therapy on IBTR risk was influenced by the margin width
and the volume of disease near the margin. Kim et al. [9]
analyzed the outcome of local excision alone in patients
with small size (<1 cm) DCIS and reported that radio-
therapy is necessary in patients with resections margin of
<1.0 cm. But in recent prospective studies, in good-risk
subset of patients with DCIS, with a median follow-up of
7 years, the local failure rate was decreased significantly
with the addition of RT [25]. In our study, two out of
nine patients with DCIS who omitted radiotherapy devel-
oped IBTR. This was the similar finding with recent stud-
ies, and careful selection should be taken for radiotherapy
omission in patients with DCIS after BCS.
Although there were three invasive cancer patients
with positive margins after BCS, marginal status had not
reach statistical significance in terms of predicting IBTR
in patients with invasive cancer. This is probably due to
the limited number of patients and events with short
follow-up period. Recent ASCO guidelines showed the
use of “no ink on tumor” should be the standard for an
adequate margin in invasive cancer. A positive margin,
defined as ink on invasive cancer or DCIS, is associated
with at least a twofold increase in IBTR; this increased
risk in IBTR is not nullified by delivery of a boost, deliv-
ery of systemic therapy, or favorable biology [12]. Fur-
ther detailed comparison of close and positive margin
after BCS in invasive cancer patients should be needed
in further larger study. In contrast, although there were
small number of events and patients with DCIS, positive
marginal status was an independent predictive factor for
IBTR in DCIS. Through meta-analysis, Wang et al. [11]
reported that negative margins should be obtained for
DCIS patients regardless of radiotherapy, and a negative
margin threshold greater than 10 mm is the best option
compared with other margin thresholds. According to
the 2015 national comprehensive cancer network (NCCN)
guideline, in patients with DCIS, margins greater than
10 mm are widely accepted as negative and margins less
than 1 mm are considered inadequate. There should be
more careful attention to achieve negative margin in pa-
tients with DCIS who underwent BCS.
Probably due to the limited number of patients and the
short follow-up period in our study, we could not demon-
strate statistically significant differences on survival curve
according to IBTR. But, among 272 invasive cancer, the
5-year OS of patients with IBTR was inferior to those
without (84 vs. 98 %). And, the 5-year distant metastasis-
free survival of patients with IBTR was inferior to those
without (63.3 vs. 96.5 %). On univariate and multivariate
analyses, LN metastasis and IBTR revealed as independ-
ent predictive factor for OS and distant metastasis-free
survival in invasive cancer. Many investigators have
reported that IBTR, especially early IBTR after BCS, is as-
sociated with subsequent mortality. In addition, clinico-
pathologic features of the recurrent tumor including LVI,
high-grade histology, high Ki-67 index, close/positive
margins, and ER negativity are known as predictive fac-
tors of poor OS after IBTR [16–18]. Investigations on lar-
ger study populations with longer follow-up periods
should be conducted to assess the more detailed clinical
impact of IBTR on overall patient outcomes. This infor-
mation can be helpful in optimizing local and systemic
therapy at the time of original diagnosis for patients
undergoing conservative treatment breast cancer. When
we treat patient with BCS, identification of individual pa-
tient’s clinical and pathologic factors that predict for IBTR
and efforts to lowering IBTR should be needed.
Our analysis is a single institution retrospective study
of small number of patients with a relatively short median
follow-up of 57 months. A longer follow-up period is
needed to estimate the long-term outcome. In addition,
selection bias is expected due to the heterogeneities of the
study population in the clinical and pathological charac-
teristics and treatment methods.
Conclusions
The ER and PR negativity was revealed as an independ-
ent predictive factor for IBTR after BCS in both DCIS
and invasive breast cancer. Meanwhile, positive margin
status in DCIS and the omission of radiotherapy in inva-
sive cancer, respectively, were the independent prognos-
tic factors for IBTR. LN metastasis and experience of
IBTR were found to be associated with poor overall sur-
vival and distant metastasis in invasive cancer patients
after BCS. More efforts should be made to reduce IBTR
when treating patient with BCS. And, aggressive local
control and adjuvant therapy should be considered in
HR-negative patients with advanced stage who receive
treatment with BCS.
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